We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




MicroRNA Linked to Breast Cancer Metastasis and Decreased Patient Survival

By LabMedica International staff writers
Posted on 01 Jan 2013
Cancer researchers have identified a molecule that enhances the metastatic potential of breast cancers by promoting epithelial-mesenchymal transition, migratory and invasive phenotypes, and by stimulating resistance to anoikis.

Anoikis is a form of programmed cell death that is induced by anchorage-dependent cells detaching from the surrounding extracellular matrix (ECM). More...
Usually cells stay close to the tissue to which they belong since the communication between proximal cells as well as between cells and ECM provide essential signals for growth or survival. When cells are detached from the ECM, there is a loss of normal cell-matrix interactions, and they may undergo anoikis. However, metastatic tumor cells may escape from anoikis and invade other organs.

Investigators at Case Western Reserve University (Cleveland, OH, USA) attempted to recapitulate tumor and metastatic microenvironments by using biomechanically compliant or rigid 3-dimensional culture systems and combining them with global microRNA (miRNA) profiling analyses to identify miRNAs that were upregulated in metastatic breast cancer cells by TGF-beta (transforming growth factor-beta receptor 2). TGF-beta acts as an antiproliferative factor in normal epithelial cells and at early stages of cancer development. When a cell is transformed into a cancer cell, parts of the TGF-beta signaling pathway are mutated, and TGF-beta no longer controls the cell. These cancer cells and surrounding stromal cells (fibroblasts) begin to proliferate. Both types of cell increase their production of TGF-beta. This TGF-beta acts on the surrounding stromal cells, immune cells, endothelial and smooth muscle cells. It causes immunosuppression and angiogenesis, which makes the cancer more invasive.

The investigators reported in the December 17, 2012, online edition of the Journal of Clinical Investigation that expression of a specific miRNA, miR-181a, was dramatically and selectively upregulated in metastatic breast tumors, particularly triple-negative breast cancers, and was highly predictive for decreased overall survival in human breast cancer patients.

Mechanistically, inactivation of miR-181a elevated the expression of the pro-apoptotic molecule Bim, which sensitized metastatic cells to anoikis. MiR-181a expression was essential in driving metastatic outgrowth and enhancing the lethality of late-stage mammary tumors in mice.

“Overall, these findings reinforce our belief that the discovery of miR-181a will become a strong predictive biomarker for breast cancer metastasis, and that the high expression of miR-181a in tumor tissues will pave the way for the development of targeted therapies, better prognosis, and increased patient survival,” said senior author Dr. William Schiemann, associate professor of general medical sciences at Case Western Reserve University. “The identification of an RNA that regulates cell death may offer a natural molecule that can resensitize metastatic breast cancers to chemotherapy.”

Related Links:

Case Western Reserve University



New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
New
PSA Assay
CanAg PSA EIA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.